TAP1 and gastric adenocarcinoma: The results suggested that TAP1 was a risk factor for patients with ACC, DLBC, KIRP, low-grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), PAAD, and UVM, as higher expression of TAP1 mRNA was correlated with poor prognosis, as well as a potential protective factor in bladder urothelial carcinoma (BLCA), BRCA, clear cell renal cell carcinoma (KIRC), ovarian serous cystadenocarcinoma (OV), rectum adenocarcinoma (READ), SKCM, stomach adenocarcinoma (STAD), and UCS.